Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China.
Vaccine
; 30(47): 6623-7, 2012 Oct 19.
Article
de En
| MEDLINE
| ID: mdl-22959987
ABSTRACT
OBJECTIVE:
To evaluate the long-term efficacy and duration of yeast-derived recombinant hepatitis B vaccine in hepatitis B virus (HBV)-endemic areas.METHOD:
A cross-sectional investigation was carried out in five HBV-endemic areas. Children who were born between 1997 and 2008 and vaccinated with yeast-derived recombinant hepatitis B vaccine were selected. Serum samples were taken to test HBV infection markers by microparticle enzyme immunoassay, and the results were compared to those before vaccination.RESULTS:
7066 subjects were enrolled. The average adjusted hepatitis B surface antigen (HBsAg) prevalence was 1.02%. HBV core antibody (anti-HBc) prevalence was 3.54%. The overall percentage of HBsAg(-)&Anti-HBc(-)&Anti-HBs(+) was 61.34%. With time after immunization, the percentage annually decreases from 86.11% in 2008 to 49.80% in 1997. Geometric mean concentration (GMC) of anti-HBs decreased significantly annually. The portion of GMC=100-999.9 mIU/ml was 48.0% in 2008, and decreased to 16.7% in 1997.CONCLUSION:
HBsAg prevalence decreased dramatically. This shows that the yeast-derived recombinant hepatitis B vaccine is effective and stable after being used for 12 years in HBV-endemic areas. It is not suggested to carry out booster immunization.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Vaccins anti-hépatite B
/
Hépatite B
Type d'étude:
Evaluation_studies
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limites:
Female
/
Humans
/
Infant
/
Male
Pays/Région comme sujet:
Asia
Langue:
En
Journal:
Vaccine
Année:
2012
Type de document:
Article
Pays d'affiliation:
Chine